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Immune response to Mycobacterium tuberculosis, the causal agent of tuberculosis, is critical for protection. For many decades,
consistent to classical biochemistry, most studies regarding immunity to the tubercle bacilli focused mainly on protein structures.
But the atypical, highly impermeable and waxy coat of mycobacteria captured the interest of structural biologists very early,
allowing the description of amazing molecules, such as previously unknown carbohydrates or fatty acids of astonishing lengths.
From their discovery, cell wall components were identiﬁed as important structural pillars, but also as molecular motifs able to
alter the human immune response. Recently, as new developments have emerged, classical conceptions of mycobacterial immune
modulators have been giving place to unexpected discoveries that, at the turn of the last century, completely changed our
perception of immunity vis-` a-vis fat compounds. In this paper, current knowledge about chemical and ultrastructural features of
mycobacterial cell-wall is overviewed, with an emphasis on the relationships between cell-wall nonpeptide molecules and immune
response. Remarks regarding the potential of these molecules for the development of new tools against tuberculosis are ﬁnally
discussed.
1.Introduction
In 1882, Robert Koch described Mycobacterium tuberculosis,
the causal agent of tuberculosis to the monthly meeting of
the Berlin Physiological Society. The bacilli were extremely
diﬃcult to stain for viewing at the microscope, and Koch
had to use an ammonia solution for damaging the cell wall
and enabling the colorant to stain the cell [1]. Some 50 years
after that, before the discovery of streptomycin by Selman
Waksman and Albert Schatz, a whole set of antibiotics had
been shown to fail for entering the waxy capsule of the
tubercle bacillus. In fact, the extremely impermeable coat
of M. tuberculosis constituted a subject of pessimism within
most microbiologists in regards to the search for a drug
against tuberculosis. The particular nature of M. tuberculosis
cell wall was therefore quickly recognized and took the
attention from structural biochemists. As the central role
of immune response for tuberculosis control was realized,
studies were focused on the relationship between host im-
munity and cell wall compounds. A variety of biochemical
and molecular approaches were used to test the involvement
of speciﬁc carbohydrates and lipids from mycobacterial cell
wall in immunogenicity, virulence, and persistence [2–4].
Mycobacteria are known for both activating and downmod-
ulating the immune response, and cell-wall compounds have
proved to induce disparate activities towards immunity as
well. Today, the M. tuberculosis envelope has been deﬁnitively
recognized as a key factor of pathogenicity, but also as a
powerful source of compounds against the disease [4–6].
This paper presents an overview of the structural features of
mycobacterialcellwall,anditsactivitiestowardsthehostim-
mune response. In accordance with the evolutionary knowl-
edge about nonprotein compounds of the tubercle bacilli,
the importance of these previously neglected molecules
for the development of tools against tuberculosis will be
highlighted.2 Clinical and Developmental Immunology
2.Mycobacterium tuberculosis CellWall:
The ExtraordinaryPermeabilityBarrier as
Describedby StructuralBiologists
2.1. The Covalently Linked Components: A Cell Wall with Un-
common Constituents. Some 80 years ago, Rudolph J. Ander-
soninitiatedatYaleUniversitythestudyofmycobacterialcell
wall. With the search for bacterial sterols in mind, Anderson
used a set of chemical reactions and solvent equilibria, but
unexpected, interesting facts were evidenced instead [7, 8].
During the second moiety of the last century, various tools
for biochemistry research were developed, for instance, the
use of enzymes, spectroscopies, mass spectrometry, and
chromatographies. Then, the analysis of mycobacterial cell
wall became a fascinating ﬁeld which captured the attention
of various structural biologists [7, 9]. Analyses of saccharide
cell-wallpolymersshowedthat,inadditiontopeptidoglycan,
a second polysaccharide, the arabinogalactan, featured all
mycobacterial species [10]. Arabinogalactan is characterized
by atypical cyclic conﬁguration for their monosaccharide
units (in a 5-members ring) [11] and is acylated to extremely
heavy fatty chains. Only after prolonged saponiﬁcation, my-
cobacterial cell wall could liberate fatty acids with skeletons
composed of up to 88 carbons, that is, the heaviest fatty
compounds that have ever been known in nature, the so-
called mycolic acids [12]. Mycolic acids constitute an essen-
tial part of mycobacterial cell wall and are species-speciﬁc.
This speciﬁcity has been exploited for the use of mycolic
acids as biomarkers, for instance, for the authentication of
M. tuberculosis in ancient human remains [13]. The extreme
chain length of mycolic acids determines the waxy nature of
mycobacterial cell wall and has been found to be critical for
mycobacterial virulence. For example, genetic manipulation
to avoid full elongation of mycolic acids in M. smegmatis
has resulted in the dramatic loss of drug and temperature
resistance in mutant strains [14].
U l t r a s t r u c t u r eo fm y c o b a c t e r i a lc e l lw a l li sn o ta ﬀordable
by conventional methods; therefore, the spatial location of
many lipid components in mycobacterial envelope is still
mere speculation. The 3D proposed models for M. tuber-
culosis cell wall are controversial [15, 16]. However, recent
data support a folded conﬁguration of mycolic chains, which
are thought to form an outer membrane-like structure, rem-
iniscent of Gram-negative bacterial cell walls and called my-
comembrane [16–18]. A model showing the essential con-
stituents of M. tuberculosis cell wall is depicted in Figure 1.
2.2. The Releasable, Free Cell-Wall Compounds. The typi-
cal motifs in mycobacterial cell walls are not limited to
covalently-linked structures. A large proportion of mycobac-
terial lipid motifs is attached via a noncovalent linkage
tothemycolyl-arabinogalactan-peptidoglycan(mAGP)core.
These “free” lipids are mostly amphipathic and probably
arrange into an outer leaﬂet in the outermost bilayer of
the cell wall (Figure 1). Free mycobacterial lipids were
ﬁrstly described by Anderson, Lederer, and the Asselineaus
[7]. Many free lipids are conjugated to sugar moieties,
therefore constituting amphiphilic glycolipids or hydrophilic
lipopolysaccharides. For instance, phospholipids linked to
inositol and mannoses are typical of all mycobacterial spe-
cies. These compounds, called phosphatidylinositol man-
nosides (PIMs), may also contain successive additions of
mannose or arabinose residues, forming lipopolysaccha-
ride molecules. Lipomannan (LM) and lipoarabinomannan
(LAM), two of the hallmark structures in mycobacteria,
belong to this molecular class [9]. Curiously, the precise
location of LM and LAM on cell-wall ultrastructure is still
to be deﬁned. Acylated glucose or trehalose also typify my-
cobacterial lipids. Trehalose, a disaccharide composed of
two units of D-Glucose coupled through an alpha,alpha -
(1→1 )-linkage, may be esteriﬁed by mycolates or other
species-speciﬁc fatty acids (Figure 2)[ 12]. Other acyl tre-
haloses display additional sugars or a sulphate substituent.
The major glucose-containing lipids in M. tuberculosis are
trehalose-6,6 - d i m y c o l a t e( T D Mo rc o r df a c t o r ) ,g l u c o s e
monomycolate (GMM), 2,3-di-O-acyl trehalose (DAT), 2 -
sulphate,2,3 -di-O-acyl trehalose or diacylated sulphatide
(SL) and lipooligosaccharides (LOS) [12, 19].
2.3. The Whole Envelope Components in Mycobacteria Form a
Unique Cell Wall. Combined, the unusual sugars of the cell
wall and the free lipid components (linked through non-
covalent interactions) form a unique structure within the
microbial world.
Mycobacterial free lipids represent a large and complex
set of molecules. Some of them are widespread within the
genus,whereasothersarecomposedbyacommoncoremotif
and diﬀer from one another by ﬁne structural variations
that typify species or genotypes [12, 19–21]. Due to this di-
versity, free glycolipids form distinct arrays in diﬀerent
M. tuberculosis strains, giving rise to speciﬁc interactions
between host cells and bacteria. For instance, some strains
display cell-surface polysaccharides hindering free lipids of
the mycomembrane. One of these saccharides is glucan, a
glucose-containing polymer known to limit opsonic phago-
cytosis [3] (see Figure 1).
Aftermycobacterialinternalization,noncovalentlylinked
lipids are released from phagocytic vesicles and exported in
exosomes to bystander noninfected cells [22, 23]. Implica-
tionsofthislipid releaseonmycobacterialvirulenceandhost
response will be discussed below.
3. Antigens andImmune Modulatorsfrom the
CellWall: ABiophysicist Pointof View
Therelationshipbetweenmycobacteriaanditshostisstrong-
ly dependant on the establishment of immune mechanisms.
Activation of immune eﬀectors, namely, T-cells, is a key step
fortuberculosiscontrol.Mycobacteriumtuberculosisisapow-
erful pathogen, able to evade the immune machinery and
survive inside the macrophage and other phagocytic and
nonphagocytic cells [4]. A balanced activation of immune
cells allows a protective response to be attained in 90–
95% of infected people. In these individuals, M. tuberculosis
is contained inside a granuloma, whose maintenance de-
pends on the correct function of immune system. Failure toClinical and Developmental Immunology 3
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Figure 1: Proposed ultrastructural array of M. tuberculosis cell wall. Cell wall includes a great variety of lipids (depicted in brown,
with polar functional groups in blue) and sugars (schematized by hexagons and pentagons in diﬀerent colors). Surrounding the plasma
membrane, cell-wall peptidoglycan is attached to another polysaccharide, the arabinogalactan. Long-chain fatty acids, the mycolic acids,
are attached to arabinogalactan through ester linkages. An outer lipid bilayer called mycomembrane is formed by mycolic acids and free
amphipathic lipids. Finally, some strains display free saccharides, such as glucan, at the outermost layer. GMM, glucose monomycolate;
PIM, phosphatidylinositol mannoside; SL, sulfatide; TDM, trehalose dimycolate or cord factor. Cell-wall proteins are depicted in arbitrary
positions. Figure is out of scale.
establish an immune response against the pathogen results
in the development of active tuberculosis, characterized by
an increase in bacterial load. To face the pathogen, which
is commonly established in lungs, the immune system
guidesacomplexsetofpro-inﬂammatorymechanisms;how-
ever, these may turn to exacerbated responses and lead to
pathology and necrosis [4]. M. tuberculosis is therefore able
to both activate and suppress immunity, a dualistic scheme
that determines the fate of tuberculosis infection.
When isolated, cell-wall compounds have been shown
to trigger a set of biological eﬀects including adjuvanticity
[4, 7], toxicity [24, 25], immune downmodulation [2, 26–
29], and arrest of phagosome maturation [30]. Cell-wall
moieties,includingcarbohydratesandlipids,areabletoelicit
the production of antibodies as well. Many carbohydrate-
and lipid-containing molecules are located at the outermost
layer of mycobacterial cell envelopes [19], that is, at the site
of early events in host-pathogen interactions.
Lipid moieties in the tubercle bacillus are extremely
abundant, with some 30% of M. tuberculosis genes devoted
to lipid synthesis or metabolism [31]. Lipid compounds
have been shown to induce many biological activities. For
example, the glycolipid dimycoloyl trehalose (DMT), or cord
factor, induces tissue damage and necrosis when injected
in a murine model [24, 25]; using in vitro assays, phenolic
glycolipids, typical of some M. tuberculosis genotypes, have
been found to suppress T-cell proliferation, independently of
their ﬁne structural and antigenic features [32]; another cell
envelope glycolipid, the phosphatidyl-inositol-mannoside
(PIM), has been found to arrest phagosome maturation in
vitro [30].
In contrast to protein molecules, the eﬀects caused by
lipids are not always associated to speciﬁc mechanisms of
action. Thus, diﬀerent, unspeciﬁc alterations have been pro-
posed to explain the various biological activities on immune
cells. Amphiphilic lipids from mycobacterial envelopes were4 Clinical and Developmental Immunology
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Figure 2: Acylated trehaloses of M. tuberculosis cell walls. Acylated variants of alpha,alpha -(1→1 )-glucosyl glucose (trehalose) are
abundant in mycobacterial envelopes. These are free amphipathic lipids known to display paradoxical immune modulatory activities. For
instance, trehalose 6,6 -dimycolate (TDM) presents potent proinﬂammatory and granulomatogenic properties [24, 25], whereas 2,3-di-O-
acyl trehalose (DAT) exhibits down-modulatory eﬀects on immune cells [26, 27].
proposedtobereleasedfromtheinfectingbacilli,followedby
their integration into host cell membranes, with subsequent
alterations on membrane topography and function [33, 34].
In support to this hypothesis, Beatty et al. showed that, fol-
lowing a short incubation period, free lipids are readily
transferred from M. tuberculosis infected to bystander non-
infected cells [22]. Moreover, studies addressing the ef-
fects of mycobacterial lipids on liposomes or mammalian
cells revealed that lipids induce a set of biological eﬀects,
including inhibition of membrane fusion by dimycoloyl
trehalose (DMT), increase of membrane permeability, and
uncoupling of membrane mitochondrial potential [33].
At present, biological eﬀects caused by various lipids can
be explained, at least in part, by newly discovered mech-
anisms, such as signaling through the binding to innate
immune receptors (see below). Notwithstanding, it is to note
that free lipids have the potential to be integrated into host
cellmembranes,sothepossibility ofunspeciﬁcalterationsby
mycobacterial lipids leading to immune modulation is still
an open question. In accordance to this idea, supramolec-
ular architecture in immune cells, (namely, raft domains)
induced during cell activation processes, is known to be
dependent on membrane lipid composition [35]. Moreover,
raft organization in macrophages has been known to be
altered after incubation with mycobacterial extractable lipids
[36].
4. MycobacterialMolecular Patterns:Microbial
SensingthroughInnateImmuneMechanisms
M. tuberculosis infections are mostly contained by the im-
mune system, leading to latent tuberculosis. Notwithstand-
ing, a restricted set of individuals are believed to eﬃciently
eliminate live M. tuberculosis, avoiding the establishment of
the pathogen either in the latent or in the active form of
the infection [4]. In agreement with this hypothesis, some
healthy individuals in close contact with M. tuberculosis
contagious patients fail to show anti-M. tuberculosis reactive
cells, as indicated by in vitro and in vivo tests. For this to
occur, potent innate immune mechanisms must take place
after the ingestion of M. tuberculosis, and mycobacterial cell-
surface glycoconjugates are probably at the origin of those
interactions [4]. Most times, however, M. tuberculosis cell
entry is followed by a long-term host-pathogen relationship,
where various cell types may act as favorable niches.Clinical and Developmental Immunology 5
4.1. Phagocytosis through Sugar Receptors. Ac r i t i c a ls t e pf o r
mycobacterial fate is the route of cell entry into phagocytic
cells.Myeloid-derivedcellsareabletorecognizethepathogen
through phagocytic receptors. Complement receptors (CRs)
and Fc receptors (FcRs) account within the most important
phagocytic receptors in myeloid cells, promoting phagocyto-
sis of complement or immunoglobulin opsonized bacteria.
However, primary interactions between mycobacteria and
phagocytes may bypass common opsonizing phagocytosis
[3]. M. tuberculosis strains may expose glucan, a cell-sur-
face polymer structurally similar to human glycogen [3].
According to binding experiments using CR3 expressed in
transfected Chinese hamster ovary cells, D-glucan interacts
through the lectin site of CR3, thus promoting a particular
entry pathway [21]. Other virulent M. tuberculosis strains
expose mannose-rich glycoconjugates, including lipoarabi-
nomannan (LAM), phosphomannoinositides (PIM), and li-
pomannan (LM). Recent works by Schlesinger group have
demonstratedthatManR,inmacrophages,andDC-SIGN,in
dendriticcells,importantlyregulatethehostresponseagainst
M. tuberculosis. Furthermore, sugar recognition through
theseC-typelectinshasbeenfoundtobealteredaccordingto
thedegreeofsaccharideacylation,thusinﬂuencingthewhole
fate of the bacilli [37–39]. Altogether, these data suggest
that ﬁne structural variations in mycobacterial molecular
patterns are very important to determine the phagocytic
pathways.
In addition to sensing by phagocytic receptors, mycobac-
terial sugars have also been known to bind collectins, a fam-
ily of proteins phagocytosed through the macrophage CR3
lectin domain. To this family belong the mannose binding
lectin (MBL) and the pulmonary surfactant proteins SP-A
and SP-B, all of them involved in the recognition of man-
nose-containing molecules [40].
4.2. Host-Pathogen Communication through Nonphagocytic
Recognizing Receptors. Some ﬁfteen years ago, studies about
Toll, a gene involved in the development of Drosophila mel-
anogaster embryos, unexpectedly revealed the association
of Toll to innate immunity in adult ﬂies [41, 42]. The
Toll protein homolog in humans, now called as Toll-like
receptor 1 (TLR-1), was recognized as an important element
of innate immunity, and 10 more TLRs have been described
to date [43]. TLRs are transmembrane receptors which sense
pathogens at the cellular surface. Evolutionarily conserved
for hundreds of millions years, TLRs recognize pathogen-
associated molecular patterns, including heat-shock pro-
teins, bacterial CpG motifs, and molecules characterizing
bacterial cell envelopes, namely, amphipathic lipids [43]. In
particular, TLR-2 has been found to sense mycobacterial
lipids, such as LAM, PIMs, and the 19kDa lipid-containing
protein LpqH, whose fatty motif has been shown to be
essential for TLR recognition [43].
To accomplish their protective role, TLR members are
activated by speciﬁc microbial patterns, and trigger signal
transduction pathways in cooperation with various signaling
adaptors. Some signals are only activated by a cooperative
interactionbetweentwoTLRmoleculesorTLRsandanother
lipid receptor, such as CD14. TLR signaling pathways may
involve diﬀerent mediators, leading to distinct immune re-
sponses depending on the molecular signal. Frequently, TLR
signaling involves the activation of MAPK pathways, which
culminate in the translocation of transcription factors, in-
cluding NF-κB and activator protein-1 (AP-1), and the
expressionofmediatorsforantimycobacterialactivities,such
as phagolysosome maturation, autophagy, apoptosis, and
antigen processing and presentation [43, 44]. However,
TLR-2 activation has also been shown to promote oppo-
site, anti-inﬂammatory functions. In cooperation with M.
tuberculosis secreted protein ESAT-6, TLR-2 downmodu-
lates the myeloid-diﬀerentiation-factor-88 (MyD88-) depen-
dent proinﬂammatory signaling and may also prevent, in
macrophages, upregulation of antigen presenting molecules
induced by cytokines [4]. Some studies have suggested that
after a prolonged contact with mycobacterial ligands, TLR-
2-dependentimmunedownmodulationoccurs,whichmight
reﬂect a mechanism of negative-feedback regulation in order
to prevent excessive inﬂammation [28, 29].
More recently, additional actors of the innate immune
response have been found to detect M. tuberculosis cell-wall
products. Intracellular proteins which highly resemble plant
R (resistance) proteins, the nucleotide binding and oligom-
erization domain (NOD)-like receptors (NLRs), have been
shown to sense a variety of products that have been released
inside the cell, thereby promoting inﬂammatory processes
against foreign bodies in the cytoplasm, including bacterial
molecules. In particular, NOD2 receptor, has been known
to sense a peptidoglycan moiety from the cell wall structure
typifying mycobacteria [45].
Noteworthy, the description of TLRs and NLRs brought
to light how a set of inﬂammatory processes take place in
responsetomicrobes,includingmycobacteria,andtovarious
inorganic signals. For instance, the study of NLRs enlight-
ened how mycobacterial cell-wall components, including
Freund adjuvants, may induce pro-inﬂammatory activity.
In this regard, deeper studies of inﬂammatory processes
induced by mycobacterial TLRs and NLRs ligands would
represent valuable clues for the development of new vaccines
against tuberculosis.
Innate immune response to mycobacterial nonprotein
molecules probably involves still unknown receptors and
modes of action. Two years ago, for instance, Ishikawa and
coworkers described Mincle, a lectin type receptor expressed
in stressed macrophages, which senses cord factor through
an unorthodox way. Mincle has been shown to activate
immunity through recognition of 6,6 -di-O-acyl trehalose
structures, although trehalose alone does not compete for
binding [46]. Given the strong relationship now recognized
between innate and adaptive immunity, it is probable that
more powerful protective vaccines, that include lipid sub-
units, can be developed during the following years.
5. T-Cell Recognition of NonproteinAntigens
Adaptive immunity is crucial for protection against M.
tuberculosis. The eﬀectors of adaptive immunity are T
lymphocytes, which are able to recognize bacterial anti-
gens presented by antigen-presenting molecules. For many6 Clinical and Developmental Immunology
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Figure 3:NonpeptideT-cellantigensassociatedtothecellwallofMycobacteriumtuberculosis.Theamphipathicnatureoflipidsismandatory
for antigen presentation. The variety of lipids associated to mycobacterial cell envelope include mycolic acids, diacylated sulfatide, glucose
monomycolate (GMM), phosphatidyl inositol mannosides (PIM), lipoarabinomannan (LAM), and cell-wall biosynthetic precursors from
the isoprenoid family, such as mannosyl phosphopolyprenol (MPP). Restriction to speciﬁc CD1 isoforms is indicated.
decades, presentation to T-cells was thought to be limited to
peptideantigens.Infact,theexpressionofpeptidepresenting
molecules, namely, Major Histocompatibility Complex class
IandclassIImolecules(MHCIandMHCII),hasrepresented
the hallmark of myeloid-derived mononuclear cells follow-
ing activation.
For almost a century, live attenuated mycobacteria have
been used as vaccines in order to induce adaptive immune
responses. A large variety of protein antigens from the tu-
bercle bacilli have been shown to stimulate the immune
system, and some of them have been used for the develop-
ment of acellular vaccine subunits [47]. At the end of the
last century, however, the dogma postulating proteins as
the unique antigenic molecules driving clonal selection and
proliferation of T-cells were reversed by the recognition of
both novel antigen-presenting molecules and nonprotein
lipid antigens. In fact, the study of the cytotoxic mechanisms
involved in a particular autoimmune disease allowed the
descriptionoftheclusterofdiﬀerentiation1(CD1)molecule
as an antigen-presenting molecule [48]. CD1 molecules fun-
damentally diﬀer from their MHC homologues in the ability
topresentnonprotein,lipidmolecules[49,50].Hydrophobic
and deep grooves characterize CD1 molecules, which have
been shown to bind amphipathic lipids and present them to
speciﬁcT-cells.HumansexpressﬁveCD1isoforms(CD1a,b,
c, d, and e), which are distributed at the plasma membrane
as well as at the endocytic pathway. Both endogenous and
exogenous lipids are therefore uploaded and presented to a
variety of T-cells (CD4+, CD8+, DN).
The search for CD1-restricted responses promptly al-
lowed the description of T-cells speciﬁc for M. tuberculo-
sis. Mycolic acids from mycobacterial cell walls were the
ﬁrst lipid antigens to be described [51]. To date, a broad
range of microbial, plant and mammalian self-lipids have
been recognized as CD1 antigens. Dideoxymycobactin [52],
glucose monomycolate [6, 49], sulfatide IV (SL-IV) [5],
isoprenoid lipids [53], phosphatidylinositol mannosides
(PIM), and LAM have all been identiﬁed as CD1 antigens in
mycobacteria. The structural features and restriction of CD1
lipid antigens from mycobacterial cell walls are schematized
in Figure 3. Lipid antigens from other microorganisms, in-
cluding Leishmania donovani, Borrelia burgdorferi, and Sph-
ingomonas have been described as well. Nonmicrobial lipids
presented by CD1 include pollen phospholipids that trigger
allergy associated mechanisms as well as self-glycolipids
involved in autoimmune diseases, including multiple sclero-
sis [49, 50].
CD1 molecules are very minor components of mon-
ocyte-derived macrophages and the study of antigenic
lipid presentation implies the use of dendritic cells, which
possessed important drawbacks until the work by Sal-
lusto and Lanzavecchia, who described the obtainment of
these antigen-presenting cells from blood monocytes [54].
The restrict-ed distribution of CD1 molecules representsClinical and Developmental Immunology 7
achallengeforthestudyoflipidantigenstoo(murineanimal
models of tuberculosis only present the CD1d isoform).
Curiously, some CD1d restricted cells share elements of
innate immune natural killer cells (NK) and from T-cell re-
ceptors (TCR) featured by an invariant α chain. These
so-called invariant Natural Killer T (iNKT) cells respond
very rapidly following M. tuberculosis infections. Cognate
antigens from mycobacterial origin have not been described
yet, but some data support the existence of direct activation
mechanisms, namely through cytokines [55, 56]. At present,
the involvement of lipids in adaptive immune response is
fully recognized, but more studies are needed in order to
promote the application of lipid antigenicity for the devel-
opment of novel tools to combat the disease.
6. ConclusiveRemarks
The cell-wall of M. tuberculosis is rich in carbohydrate and
lipid molecules. Recent studies have brought to light the
mode of action of important immune modulators from
mycobacteria. Both innate and adaptive responses to non-
protein mycobacterial compounds may be exploited for the
development of tools to control the disease. Recent reports
have advanced the potential of cell wall lipid antigens for
vaccine subunits. Namely, Komori and coworkers highlight
the activation of T-cells by glucose monomycolate (GMM)
[6], whereas sulfatide has been proposed as a candidate
f o rt u b e r c u l o s i sv a c c i n eb yP u z o ’ sa n dd eL i b e r o ’ sg r o u p s
[5, 57]. Given the wide variety of bioactive lipids in the
tubercle bacillus, the complete assessment of vaccine can-
didates should include the study of lipids as potential
subunits. In this regard, Asensio and coworkers have shown
a correlationship between virulence attenuation in the PhoP-
PhoR M. tuberculosis mutant, a vaccine candidate, and
important alterations in lipid proﬁles [58]. Interestingly,
the cytotoxic response triggered in humans by vaccination
with live bacillus Calmette-Gu´ erin has been found to be
essentially mediated by CD1 antigens [59]. Nevertheless,
there has been a misconception regarding the involvement
of CD1 antigen presentation during tuberculosis. Most in
vitro studies of immune activation have been conducted in
macrophages, whereas only dendritic cells are able to present
lipids. Similarly, studies addressing the immune response
against tuberculosis are commonly performed in mice, a
model devoid of four from ﬁve human CD1 isoforms. In
conclusion,itistonotethatthedevelopmentofnewtoolsfor
tuberculosis control may take proﬁt of mycobacterial lipids,
but more eﬀorts must be undertaken to better elucidate their
full potential at both basic and translational ﬁelds.
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